☰

Kevin J. Freise, Ph.D. - Publications

Affiliations: 
2009 Pharmacy University of Iowa, Iowa City, IA 
Area:
Pharmacology
Tree Info Grants Similar researchers PubMed Report error

37 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Gopalakrishnan S, Wierda W, Chyla B, Menon R, Miles D, Humerickhouse R, Awni W, Hamed Salem A, Mensing S, Freise KJ. Integrated mechanistic model of minimal residual disease kinetics with venetoclax therapy in chronic lymphocytic leukemia. Clinical Pharmacology and Therapeutics. PMID 32749675 DOI: 10.1002/Cpt.2005  0.364
2020 Alhadab AA, Salem AH, Freise KJ. Semi-Mechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin. Clinical and Translational Science. PMID 31961475 DOI: 10.1111/Cts.12739  0.332
2019 Deng R, Gibiansky L, Lu T, Li X, Lu D, Li C, Girish S, Wang J, Boyer M, Shankar N, Humphrey K, Freise KJ, Salem AH, Seymour JF, Kater AP, et al. Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study. Leukemia & Lymphoma. 1-10. PMID 31549889 DOI: 10.1080/10428194.2019.1657575  0.343
2019 Deng R, Gibiansky L, Lu T, Agarwal P, Ding H, Li X, Kshirsagar S, Lu D, Li C, Girish S, Wang J, Boyer M, Humphrey K, Freise KJ, Salem AH, et al. Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study. Clinical Pharmacokinetics. PMID 31209657 DOI: 10.1007/S40262-019-00788-8  0.35
2019 Wang M, Ramchandren R, Chen R, Karlin L, Chong G, Jurczak W, Wu K, Bishton M, Collins G, Eliadis P, Peyrade F, Freise K, Sukbuntherng J, Lee Y, Dobkowska E, et al. RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE SYMPATICO STUDY EVALUATING IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA Hematological Oncology. 37: 333-335. DOI: 10.1002/Hon.146_2630  0.311
2018 Pang Y, Rosebraugh MR, Freise KJ, Parikh A, Mohamed MF. Are Clinical Therapeutic Protein-Drug Interaction Studies Needed When Disease Modification Is Driving the Potential Interaction? Journal of Clinical Pharmacology. PMID 30129669 DOI: 10.1002/Jcph.1290  0.662
2018 Mangal N, Salem AH, Menon RM, Freise KJ. Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials. Hematological Oncology. PMID 29672885 DOI: 10.1002/Hon.2514  0.36
2018 Freise KJ, Hu B, Salem AH. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics. European Journal of Clinical Pharmacology. PMID 29302721 DOI: 10.1007/S00228-017-2403-3  0.306
2018 Bueno O, Slimp R, Jacobson M, Pesko JC, Li H, Ross JA, Freise K, Maciag PC. A phase 1/2, multicenter, dose-escalation and expansion study of combination therapy with venetoclax, daratumumab, and dexamethasone (with and without bortezomib) in subjects with relapsed or refractory multiple myeloma. Journal of Clinical Oncology. 36: TPS8061-TPS8061. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps8061  0.32
2018 Costa LJ, Stadtmauer EA, Morgan GJ, Monohan GP, Kovacsovics T, Burwick N, Jakubowiak AJ, Mobasher M, Freise K, Ross JA, Pesko JC, Munasinghe W, Cordero J, Morris L, Maciag PC, et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 36: 8004-8004. DOI: 10.1200/Jco.2018.36.15_Suppl.8004  0.324
2018 Costa LJ, Stadtmauer EA, Morgan G, Monohan G, Kovacsovics T, Burwick N, Jakubowiak A, Kaufman JL, Mobasher M, Freise KJ, Ross JA, Pesko J, Munasinghe W, Gudipati S, Mudd S, et al. Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Blood. 132: 303-303. DOI: 10.1182/Blood-2018-99-117026  0.316
2017 Li M, Dave N, Salem AH, Freise KJ. Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients. Medicine. 96: e7988. PMID 28858138 DOI: 10.1097/Md.0000000000007988  0.301
2017 Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, Touzeau C, Punnoose EA, Cordero J, Munasinghe W, Jia J, Salem AH, Freise KJ, Leverson JD, Enschede SH, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/ refractory MM. Blood. PMID 28847998 DOI: 10.1182/Blood-2017-06-788323  0.356
2017 Parikh A, Gopalakrishnan S, Freise KJ, Verdugo ME, Menon RM, Mensing S, Salem AH. Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma. Leukemia & Lymphoma. 1-9. PMID 28797193 DOI: 10.1080/10428194.2017.1361024  0.306
2017 Agarwal SK, Mangal N, Menon RM, Freise KJ, Salem AH. Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials. Journal of Cancer. 8: 1562-1567. PMID 28775775 DOI: 10.7150/Jca.18686  0.315
2017 Mangal N, Salem AH, Li M, Menon R, Freise KJ. Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials. Hematological Oncology. PMID 28707346 DOI: 10.1002/Hon.2463  0.337
2017 Freise KJ, Jones AK, Verdugo ME, Menon RM, Maciag PC, Salem AH. Moving beyond maximum tolerated dose for targeted oncology drugs: Use of clinical utility index to optimize venetoclax dosage in multiple myeloma patients. Clinical Pharmacology and Therapeutics. PMID 28419431 DOI: 10.1002/Cpt.712  0.345
2017 Freise KJ, Shebley M, Salem AH. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model. Journal of Clinical Pharmacology. PMID 28052338 DOI: 10.1002/Jcph.858  0.349
2017 Bueno O, Xu T, Cordero J, Morris L, Ross J, Freise K, Munasinghe W, Leverson J, Mudd S, Verdugo M. Phase 2, open-label study of venetoclax in combination with carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 35: TPS8056-TPS8056. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps8056  0.382
2017 Kaufman JL, Gasparetto CJ, Mikhael J, Moreau P, Touzeau C, Vij R, Facon T, Pegourie B, Benboubker L, Boise LH, Alzate S, Dunbar M, Jia J, Freise KJ, Verdugo M, et al. Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma Blood. 130: 3131-3131. DOI: 10.1182/Blood.V130.Suppl_1.3131.3131  0.364
2016 Freise KJ, Jones AK, Menon RM, Verdugo ME, Humerickhouse RA, Awni WM, Salem AH. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy. Hematological Oncology. PMID 27982454 DOI: 10.1002/Hon.2373  0.368
2016 Salem AH, Hu B, Freise KJ, Agarwal SK, Sidhu DS, Wong SL. Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers. Clinical Drug Investigation. PMID 27910036 DOI: 10.1007/S40261-016-0485-9  0.327
2016 Freise KJ, Jones AK, Eckert D, Mensing S, Wong SL, Humerickhouse RA, Awni WM, Salem AH. Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Clinical Pharmacokinetics. PMID 27638334 DOI: 10.1007/S40262-016-0453-9  0.309
2016 Freise KJ, Dunbar M, Jones AK, Hoffman D, Enschede SL, Wong S, Salem AH. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis. Cancer Chemotherapy and Pharmacology. PMID 27586967 DOI: 10.1007/S00280-016-3144-1  0.317
2016 Jones AK, Freise KJ, Agarwal SK, Humerickhouse RA, Wong SL, Salem AH. Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis. The Aaps Journal. PMID 27233802 DOI: 10.1208/S12248-016-9927-9  0.349
2016 Mangal N, Salem AH, Menon R, Freise KJ. Relationship Between Short-Term Response Rates and Long-Term Survival in Acute Myeloid Leukemia and Relapsed or Refractory Multiple Myeloma Blood. 128: 5128-5128. DOI: 10.1182/Blood.V128.22.5128.5128  0.352
2016 Freise KJ, Jones AK, Eckert D, Mensing S, Wong S, Humerickhouse R, Awni W, Salem AH. Abstract 2045: Relationship of venetoclax dose and exposure to response in relapsed or refractory chronic lymphocytic leukemia and non-Hodgkin's lymphoma subjects Cancer Research. 76: 2045-2045. DOI: 10.1158/1538-7445.Am2016-2045  0.36
2012 Mock DM, Matthews NI, Zhu S, Strauss RG, Schmidt RL, Zimmerman MB, Nalbant D, Freise KJ, Saleh M, Veng-Pedersen P, Widness JA. Comparison of red blood cell survival in sheep determined using red blood cells labeled with either biotin at multiple densities or [14C]cyanate: validation of a model to study human physiology and disease. Transfusion. 52: 963-73. PMID 22229348 DOI: 10.1111/J.1537-2995.2011.03512.X  0.592
2010 Mock DM, Matthews NI, Zhu S, Burmeister LF, Zimmerman MB, Strauss RG, Schmidt RL, Nalbant D, Freise KJ, Veng-Pedersen P, Widness JA. Red blood cell (RBC) volume can be independently determined in vivo in the sheep using ovine RBCs labeled at different densities of biotin. Transfusion. 50: 2553-64. PMID 20561297 DOI: 10.1111/J.1537-2995.2010.02744.X  0.577
2010 Freise KJ, Widness JA, Veng-Pedersen P. Erythropoietic response to endogenous erythropoietin in premature very low birth weight infants. The Journal of Pharmacology and Experimental Therapeutics. 332: 229-37. PMID 19808699 DOI: 10.1124/Jpet.109.159905  0.571
2009 Freise KJ, Schmidt RL, Gingerich EL, Veng-Pedersen P, Widness JA. The effect of anticoagulant, storage temperature and dilution on cord blood hematology parameters over time. International Journal of Laboratory Hematology. 31: 496-504. PMID 18422712 DOI: 10.1111/J.1751-553X.2008.01066.X  0.564
2008 Freise KJ, Schmidt RL, Widness JA, Veng-Pedersen P. Pharmacodynamic modeling of the effect of changes in the environment on cellular lifespan and cellular response. Journal of Pharmacokinetics and Pharmacodynamics. 35: 527-52. PMID 18937059 DOI: 10.1007/S10928-008-9100-X  0.594
2008 Veng-Pedersen P, Freise KJ, Schmidt RL, Widness JA. Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin. The Journal of Pharmacy and Pharmacology. 60: 1321-34. PMID 18812025 DOI: 10.1211/Jpp/60.10.0008  0.586
2008 Freise KJ, Widness JA, Schmidt RL, Veng-Pedersen P. Modeling time variant distributions of cellular lifespans: increases in circulating reticulocyte lifespans following double phlebotomies in sheep. Journal of Pharmacokinetics and Pharmacodynamics. 35: 285-323. PMID 18553126 DOI: 10.1007/S10928-008-9089-1  0.571
2007 Freise KJ, Widness JA, Schmidt RL, Veng-Pedersen P. Pharmacodynamic analysis of time-variant cellular disposition: reticulocyte disposition changes in phlebotomized sheep. Journal of Pharmacokinetics and Pharmacodynamics. 34: 519-47. PMID 17516153 DOI: 10.1007/S10928-007-9056-2  0.576
2007 Freise KJ, Widness JA, Segar JL, Schmidt RL, Veng-Pedersen P. Increased erythropoietin elimination in fetal sheep following chronic phlebotomy. Pharmaceutical Research. 24: 1653-9. PMID 17457660 DOI: 10.1007/S11095-007-9295-3  0.566
2007 Widness JA, Schmidt RL, Hohl RJ, Goldman FD, Al-Huniti NH, Freise KJ, Veng-Pedersen P. Change in erythropoietin pharmacokinetics following hematopoietic transplantation Clinical Pharmacology and Therapeutics. 81: 873-879. PMID 17429351 DOI: 10.1038/Sj.Clpt.6100165  0.657
Show low-probability matches.